Biotechnology & Bioengineering published a recent study that reaffirms CHO cell lines provide high safety margins when used in the bioproduction of drugs. The study looked at 14 viruses from 12 families representing the reported instances of CHO infection in bioproduction. Viruses were assessed for their ability to infect and replicate in CHO, and to produce cytopathic effects (CPE) or not. The study concluded that current adventitious agent testing regimes used with CHO cells will provide the safety margin required for safe production of final drugs, particularly in lieu of limited susceptibility of CHO to virus infection.
Posted by Bruce Lehr April 11th 2010